Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs.
Franziska R TraubeMarcel SternAnnika J TölkeMartina RudeliusErnesto Mejias-PerezNada RaddaouiBeate Mareike KümmererCéline DouatFilipp StreshnevManuel AlbanesePaul R WratilYasmin V GärtnerMilda NainytėGrazia GiorgioStylianos MichalakisSabine SchneiderHendrik StreeckMarkus MüllerOliver T KepplerThomas CarellPublished in: Angewandte Chemie (International ed. in English) (2022)
The emergence of more transmissible or aggressive variants of SARS-CoV-2 requires the development of antiviral medication that is quickly adjustable to evolving viral escape mutations. Here we report the synthesis of chemically stabilized small interfering RNA (siRNA) against SARS-CoV-2. The siRNA can be further modified with receptor ligands such as peptides using Cu I -catalysed click-chemistry. We demonstrate that optimized siRNAs can reduce viral loads and virus-induced cytotoxicity by up to five orders of magnitude in cell lines challenged with SARS-CoV-2. Furthermore, we show that an ACE2-binding peptide-conjugated siRNA is able to reduce virus replication and virus-induced apoptosis in 3D mucociliary lung microtissues. The adjustment of the siRNA sequence allows a rapid adaptation of their antiviral activity against different variants of concern. The ability to conjugate the siRNA via click-chemistry to receptor ligands facilitates the construction of targeted siRNAs for a flexible antiviral defence strategy.
Keyphrases
- sars cov
- cancer therapy
- induced apoptosis
- respiratory syndrome coronavirus
- drug delivery
- endoplasmic reticulum stress
- hyaluronic acid
- copy number
- oxidative stress
- drug discovery
- signaling pathway
- binding protein
- healthcare
- photodynamic therapy
- high glucose
- gene expression
- angiotensin ii
- dna binding
- dna methylation
- disease virus